ProfileGDS4814 / ILMN_1812226
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 64% 34% 36% 28% 21% 39% 49% 27% 53% 40% 19% 16% 48% 47% 49% 12% 28% 60% 7% 64% 31% 9% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)59.103964
GSM780708Untreated after 4 days (C2_1)46.460534
GSM780709Untreated after 4 days (C3_1)46.8536
GSM780719Untreated after 4 days (C1_2)45.148328
GSM780720Untreated after 4 days (C2_2)43.767821
GSM780721Untreated after 4 days (C3_2)47.606239
GSM780710Trastuzumab treated after 4 days (T1_1)50.197149
GSM780711Trastuzumab treated after 4 days (T2_1)44.907827
GSM780712Trastuzumab treated after 4 days (T3_1)51.563853
GSM780722Trastuzumab treated after 4 days (T1_2)47.812540
GSM780723Trastuzumab treated after 4 days (T2_2)43.331719
GSM780724Trastuzumab treated after 4 days (T3_2)42.603116
GSM780713Pertuzumab treated after 4 days (P1_1)49.911548
GSM780714Pertuzumab treated after 4 days (P2_1)49.69147
GSM780715Pertuzumab treated after 4 days (P3_1)50.023349
GSM780725Pertuzumab treated after 4 days (P1_2)41.814412
GSM780726Pertuzumab treated after 4 days (P2_2)45.210628
GSM780727Pertuzumab treated after 4 days (P3_2)55.564460
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)40.12357
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)59.174664
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)45.728931
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)40.80769
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)50.107649